## **Special Issue**

## **Marine Drugs in Clinical Trials**

## Message from the Guest Editor

The aim of this Special Issue is to demonstrate the utility of marine-sourced materials (from invertebrates, microbes of all types, and micro- and macro-algae as sources of such agents). Compounds should have reached the preclinical stage and be candidates for clinical trials in humans, though, depending on their source, agents at the preclinical stage can be considered on their merits. Dr. David John Newman

### **Guest Editor**

Dr. David J. Newman

Retired Branch Chief, Natural Products Branch, National Cancer Institute, Frederick, MD 21702-1201, USA

## Deadline for manuscript submissions

closed (15 February 2018)



# **Marine Drugs**

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/8319

Marine Drugs Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 marinedrugs@mdpl.com

mdpi.com/journal/ marinedrugs





an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

### **Editor-in-Chief**

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

